Last reviewed · How we verify
NCT03042221
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
trial in Non-Small Cell Carcinoma of Lung, TNM Stage 4 in 100 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 May 2016 |
| Primary completion | 1 November 2026 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across United States |
Conditions studied
- Non-Small Cell Carcinoma of Lung, TNM Stage 4 — all drugs for Non-Small Cell Carcinoma of Lung, TNM Stage 4 →
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
- EGFR Gene Mutation — all drugs for EGFR Gene Mutation →
- ALK Gene Mutation — all drugs for ALK Gene Mutation →
Sponsor
University of Colorado, Denver
Who can join
Adults 18 to 85, any sex, with Non-Small Cell Carcinoma of Lung, TNM Stage 4 or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
Kleczko EK, Heasley LE. · · 2018 · cited 20× · PMID 29458371 · DOI 10.1186/s12943-018-0816-y
Verify or expand the search:
- PubMed search for NCT03042221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small Cell Carcinoma of Lung, TNM Stage 4
Currently open trials in the same condition.
- NCT03774732 — PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cance · Phase 3 · active not recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03042221 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 20 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing